Applied Therapeutics logo
Applied Therapeutics APLT

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Applied Therapeutics Balance Sheet 2011-2026 | APLT

Annual Balance Sheet Applied Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-49.4 M -15.8 M -52.6 M -55.1 M -16.8 M -18.7 M -3.28 M - - - - - -

Long Term Debt

38 K 414 K 891 K 1.33 M - - - - - - - - -

Long Term Debt Current

429 K 477 K 442 K 406 K 356 K - - - - - - - -

Total Non Current Liabilities

797 K 878 K 891 K 1.33 M 1.68 M - 6.25 M - - - - - -

Total Current Liabilities

71.2 M 33.4 M 26.5 M 21.2 M 14.1 M - - - - - - - -

Total Liabilities

72 M 34.3 M 27.4 M 22.6 M 15.8 M 4.43 M 7.25 M - - - - - -

Deferred Revenue

667 K - - - - - - - - - - - -

Retained Earnings

-469 M -349 M -266 M -161 M -66.8 M -21.3 M -4.74 M - - - - - -

Total Assets

54.8 M 38.4 M 89.9 M 105 M 48.4 M 20.2 M 3.29 M - - - - - -

Cash and Cash Equivalents

49.9 M 16.7 M 53.9 M 57.5 M 18.8 M 18.7 M - - - - - - -

Book Value

-17.1 M 4.06 M 62.5 M 81.9 M 32.6 M 15.8 M -3.96 M - - - - - -

Total Shareholders Equity

-17.1 M 4.06 M 62.5 M 81.9 M 32.6 M -19.6 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Applied Therapeutics

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

2.03 M 2.16 M 2.39 M 1.71 M 30 K 38 K 44 K 170 K 291 K 414 K 536 K 655 K 773 K 891 K 1 M 1.11 M 1.22 M 1.33 M 1.33 M 1.33 M 1.33 M 1.68 M 1.68 M 1.68 M 1.68 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

2.03 M 2.16 M 2.39 M 1.71 M 30 K 797 K 735 K 792 K 825 K 878 K 536 K 655 K 773 K 891 K 1 M 1.11 M 1.22 M 1.33 M 1.33 M 1.33 M 1.33 M 1.68 M 1.68 M 1.68 M 1.68 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

34.9 M 19.9 M 29.7 M 101 M 55.4 M 72 M 56.2 M 48 M 34.1 M 34.3 M 47 M 52.4 M 23 M 27.4 M 31.8 M 24.5 M 21 M 22.6 M 22.6 M 22.6 M 22.6 M 15.8 M 15.8 M 15.8 M 15.8 M 4.43 M 4.43 M 4.43 M 4.43 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

212 K 212 K 212 K 212 K 333 K 667 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-636 M -617 M -574 M -618 M -550 M -469 M -431 M -389 M -359 M -349 M -334 M -315 M -289 M -266 M -239 M -211 M -185 M -161 M -161 M -161 M -161 M -66.8 M -66.8 M -66.8 M -66.8 M -21.3 M -21.3 M -21.3 M -21.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

34.4 M 37.3 M 86.7 M 107 M 128 M 54.8 M 45.2 M 43.6 M 30 M 38.4 M 56.7 M 78.2 M 65 M 89.9 M 119 M 137 M 156 M 105 M 105 M 105 M 105 M 48.4 M 48.4 M 48.4 M 48.4 M 20.2 M 20.2 M 20.2 M 20.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

11.9 M 30.4 M 79.4 M 98.9 M 122 M 49.9 M 37.5 M 35.6 M 22.9 M 16.7 M 40.4 M 55.7 M 38.2 M 53.9 M 70.2 M 78.4 M 84.1 M 57.5 M 57.5 M 57.5 M 57.5 M 18.8 M 18.8 M 18.8 M 18.8 M 18.7 M 18.7 M 18.7 M 18.7 M 3.28 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

-561 K 17.4 M 57 M 5.89 M 72.4 M -17.1 M -11 M -4.33 M -4.07 M 4.06 M 9.63 M 25.8 M 42 M 62.5 M 86.7 M 112 M 135 M 81.9 M 81.9 M 81.9 M 81.9 M 32.6 M 32.6 M 32.6 M 32.6 M 15.8 M 15.8 M 15.8 M 15.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

-561 K 17.4 M 57 M 5.89 M 72.4 M -17.1 M -11 M -4.33 M -4.07 M 4.06 M 9.63 M 25.8 M 42 M 62.5 M 86.7 M 112 M 135 M 81.9 M 81.9 M 81.9 M 81.9 M 32.6 M 32.6 M 32.6 M 32.6 M -19.6 M -19.6 M -19.6 M -19.6 M -3.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Applied Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 2.3 -1.29 % $ 3.01 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 220.9 2.49 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.57 1.77 % $ 915 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 10.47 4.08 % $ 763 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 1.31 2.34 % $ 80.4 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 1.37 -1.44 % $ 72 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.33 0.76 % $ 339 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.31 1.59 % $ 111 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.09 1.42 % $ 4.23 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.26 4.49 % $ 251 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.58 6.04 % $ 99.5 M niderlandNiderland
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Palatin Technologies Palatin Technologies
PTN
$ 21.0 5.79 % $ 19.5 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 2.12 -1.4 % $ 7.74 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.53 5.1 % $ 868 M canadaCanada
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA